Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Preferred Stock Liabilities: 2020-2025

  • Pharming Group N.V's Preferred Stock Liabilities rose 6.52% to $96.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $96.4 million, marking a year-over-year increase of 6.52%. This contributed to the annual value of $82.4 million for FY2024, which is 40.47% down from last year.
  • Latest data reveals that Pharming Group N.V reported Preferred Stock Liabilities of $96.4 million as of Q2 2025, which was up 16.96% from $82.4 million recorded in Q4 2024.
  • Pharming Group N.V's 5-year Preferred Stock Liabilities high stood at $147.4 million for Q2 2021, and its period low was $82.4 million during Q4 2024.
  • For the 3-year period, Pharming Group N.V's Preferred Stock Liabilities averaged around $108.7 million, with its median value being $96.4 million (2025).
  • In the last 5 years, Pharming Group N.V's Preferred Stock Liabilities crashed by 40.47% in 2024 and then increased by 6.52% in 2025.
  • Over the past 5 years, Pharming Group N.V's Preferred Stock Liabilities (Quarterly) stood at $140.9 million in 2021, then decreased by 5.32% to $133.4 million in 2022, then grew by 3.78% to $138.4 million in 2023, then slumped by 40.47% to $82.4 million in 2024, then rose by 6.52% to $96.4 million in 2025.
  • Its Preferred Stock Liabilities was $96.4 million in Q2 2025, compared to $82.4 million in Q4 2024 and $90.5 million in Q2 2024.